Loading clinical trials...

Proteomics and Genomics Combined With CT to Predict CVD | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Proteomics and Genomics Combined With CT to Predict CVD

NCT05800093•Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

View on ClinicalTrials.gov

Summary

This study evaluates plaque progression and characteristics in patients with coronary atherosclerosis.

Eligibility

Age

50 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult patients between 50 and 75 years old
•Subjects at intermediate to high risk for ASCVD
•Asymptomatic patients without cardiac chest pain
•Evidence of atherosclerosis on baseline CCTA

Exclusion Criteria

•Renal insufficiency, defined as eGFR \< 30 ml/min
•History of cardiovascular events (myocardial infarction, peripheral artery disease and ischemic stroke)
•Use of lipid lowering therapy other than statin, ezetimibe or bempedoic acid monotherapy
•Change in lipid lowering therapy in the last 6 months
•Use of more than two antihypertensive agents
•No coronary atherosclerosis at baseline imaging
•Active malignancy requiring treatment
•Atrial fibrillation
•Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
•Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.

Locations (1)

Amsterdam UMC, location AMC

Amsterdam, Netherlands

Key Dates

Start Date

January 12, 2023

Primary Completion Date

January 30, 2026

Completion Date

June 1, 2026

Last Updated

October 2, 2025

Enrollment

310

ACTUAL participants

Conditions

Coronary Artery Disease Progression

Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study

NCT05860400

Coronary Artery DiseaseCoronary Artery Stenosis+5 more

View study

RECRUITING

Natural History of Coronary Atherosclerosis

NCT06040073

Coronary Artery Disease ProgressionRadial Wall Strain+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Proteomics and Genomics Combined With CT to Predict CVD

Inclusion Criteria

Exclusion Criteria

Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study

Natural History of Coronary Atherosclerosis

Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population

Critical Treatment of Coronary Artery Disease

Sirtuin-1 and Advanced Glycation End-products in Postmenopausal Women With Coronary Disease